Skip to main content
. Author manuscript; available in PMC: 2024 Apr 25.
Published in final edited form as: JACC Heart Fail. 2023 Feb;11(2):211–223. doi: 10.1016/j.jchf.2022.11.007

Table 2.

Clinical Outcomes of Patients Eligible for Vericiguat in GWTG-HF

Outcomes VICTORIA Eligible Patients
(GWTG-HF)*
FDA Label Patients
(GWTG-HF)*
Hospitalized HF with EF<45%
(GWTG-HF)*
In-Hospital Outcomes *
Discharge Disposition
 Home 75,494 (81.8) 184,630 (83.3) 198,893 (82.5)
 Other Health Care Facility 14,139 (15.3) 31,629 (14.3) 35,025 (14.5)
 Expired 2,616 (2.8) 5,471 (2.5) 7,139 (3.0)
In-hospital Death 2,616 (2.8) 5,471 (2.5) 7,139 (3.0)
Length of Stay, days
 Median (25th, 75th) 4 (2 – 6) 4 (2 – 6) 4 (2 – 6)
 Mean (SD) 4.5 (4.0) 4.9 (4.5) 5.0 (4.9)
30-day Endpoints *
All-cause mortality 890 (5.7) 2,192 (6.2) 2,448 (6.5)
All-cause readmission 3,402 (22.0) 7,674 (21.6) 8,352 (22.1)
HF readmission 1,407 (9.1) 3,219 (9.1) 3,466 (9.2)
Mortality or HF readmission 2,113 (13.6) 4,995 (14.0) 5,464 (14.4)
12-month Endpoints *
All-cause mortality 5,703 (36.73) 12,751 (35.80) 13,872 (36.55)
All-cause readmission 10,114 (66.16) 22,497 (64.23) 24,236 (64.90)
HF readmission 5,374 (35.23) 11,660 (33.37) 12,406 (33.29)
Mortality or HF readmission 8,586 (55.30) 19,019 (53.40) 20,518 (54.06)
*

For in-hospital outcomes, the denominators used for the three groups were 92,249, 221,730 and 241,057 respectively. For 30-day and 12-month outcome analyses, the demoniators for the three groups were 15,527, 35,614, and 37,952. #FDA= Food and Drug Administration; GWTG= Get With The Guidelines; HFrEF= Heart Failure with Reduced Ejection Fraction; SD= Standard Deviation; HF= Heart Failure.